Conference Call and Webcast Scheduled for Monday, March 2, 2020 at 8:30 AM ET NEW YORK --(BUSINESS WIRE)--Feb. 24, 2020-- UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve
NEW YORK --(BUSINESS WIRE)--Jan. 8, 2020-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that Liz Barrett , President and Chief
Potential for UGN 101 to be First Non-Surgical Therapy for the Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC) NEW YORK --(BUSINESS WIRE)--Dec. 19, 2019-- UroGen Pharma Ltd. (Nasdaq: URGN) today announced the U.S. Food and Drug Administration ( FDA ) accepted for filing and granted
NEW YORK --(BUSINESS WIRE)--Dec. 6, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced the grants of inducement restricted stock units (“RSUs”) to five new employees in connection with
NEW YORK --(BUSINESS WIRE)--Nov. 18, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will participate in fireside chats at the following conferences in November: Stifel 2019
Completed Submission of New Drug Application (NDA) to U.S. FDA for UGN-101 in Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Exclusive Worldwide License Agreement with Agenus to Advance Treatment of High-Grade Urinary Tract Cancers in Combination with UGN-201 Conference Call and
UroGen to Develop and Commercialize Zalifrelimab (AGEN1884, anti-CTLA-4 antibody) with UGN-201 for High-Grade Non-Muscle Invasive Bladder Cancer NEW YORK --(BUSINESS WIRE)--Nov. 11, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address
Conference Call and Webcast Scheduled for Tuesday, November 12, 2019 at 8:30 AM ET NEW YORK --(BUSINESS WIRE)--Nov. 6, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report third quarter 2019 financial results on Tuesday, November 12, 2019 , prior to the open of the market.
NEW YORK --(BUSINESS WIRE)--Sep. 30, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will present at the following conference in October: 2019 Cantor Global Healthcare
UGN-101 and UGN-102 Demonstrate Positive Clinical Data in Low-Grade Upper Tract Urothelial Cancer (LG UTUC) and Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC) UGN-101 Final Data Modules for NDA Submission On-Track for Q4 2019 UGN-101 Plans for Launch Readiness by January 2020
